Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Resiquimod (Primary) ; Melanoma vaccine
- Indications Malignant melanoma
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 12 Oct 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 25 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.